KM
KMDA.KL
—
Bursa Malaysia
Diversified Pharmaceuticals
Kmda.Kl
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-14,4 %
ROE
-4,2 %
Net margin
-19,4 %
Debt / equity
0,22
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$7,98
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
KMDA.KL operates in the Textiles & Leather Goods industry, specializing in the production and sale of consumer goods within the Cyclical Consumer Products sector.
Business. Kamada Ltd (KMDA.O) is a pharmaceutical company engaged in the research, development, and commercialization of specialty pharmaceutical products. The firm is headquartered in Israel and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target12,33
Analyst recommendations
3 analysts · consensus BuyBuy3
Hold0
Sell0
12-month price target
12,33
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Wells Fargo Advisors
largest disclosed fund holder
Profitability→
-4,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to KMDA.KL. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Kamada Ltd (KMDA.O) is a pharmaceutical company engaged in the research, development, and commercialization of specialty pharmaceutical products. The firm is headquartered in Israel and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
AI synthesis
GENERATEDKMDA.KL's capital structure is characterized by a relatively low debt-to-equity ratio of 0.22, indicating a conservative leverage position compared to industry norms. The company's liquidity is assessed as medium, with a current ratio of 5.28, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -6,061,010 MYR, which may signal potential challenges in maintaining liquidity without external financing.
Profitability metrics for KMDA.KL are concerning, with a return on equity of -4.23% and a return on assets of -3.41%. These figures indicate that the company is not generating returns that meet the cost of capital, which is a red flag for investors. The operating loss of 6,479,950 MYR and a net loss of 8,715,930 MYR further underscore the company's financial distress.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in the Textiles & Leather Goods industry, which is sensitive to consumer demand fluctuations.
KMDA.KL's growth trajectory appears to be negative, with a reported revenue of 45,037,300 MYR, which is below the analyst estimate of 176,616,000 MYR. The company's operating cash flow of 6,059,120 MYR is a positive sign, but it is insufficient to offset the negative free cash flow. The capital expenditure of -92,780 MYR suggests minimal investment in growth initiatives, which may hinder future revenue expansion.
Risk factors for KMDA.KL include a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no significant dilution potential reported. However, the negative net income and operating income highlight the company's operational inefficiencies and potential for further financial deterioration.
Recent events, as disclosed in the company's financial filings, indicate a challenging operating environment. The company's last actual EPS was 0.06 MYR, and the last actual revenue was 176,616,000 MYR, both of which are below the reported figures. These discrepancies may suggest issues with revenue recognition or operational performance.
Key takeaways
- KMDA.KL is operating at a loss, with a negative return on equity and return on assets.
- The company's liquidity is medium, with a current ratio of 5.28, but it has a negative free cash flow.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Growth is not evident, with reported revenue below analyst estimates.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
- Recent financial performance indicates operational inefficiencies and potential for further financial deterioration.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,20
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$206.1M
Net cashⓘ
-$45.7M
Current ratioⓘ
5.3
Debt / equityⓘ
0.2
ROAⓘ
-3.4%
ROEⓘ
-4.2%
Cash conversionⓘ
-70.0%
CapEx / revenueⓘ
-0.2%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Pharmaceutical Distribution—
low · business_description · 2026-07-03
Proprietary Pharmaceuticals—
low · business_description · 2026-07-03
Business relationships
Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
Suppliers3
Takeda Pharmaceutical Co Ltd4502.TSupplier95%Source ↗
Valneva SEVALN.OSupplier95%Source ↗
Emergent Biosolutions IncEBS.OSupplier90%Source ↗
Supply chain
Vendors → KMDA ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs KMDA · multiples and returns
MC
MCK—
Mckesson Corp
$827,14
102,6B USDP/E
21,2x
-1,1 vs self
Div yield
0,4 %
-2,6 vs self
ROE
-219,2 %
-226,8 vs self
CO
COR—
Cencora Inc
$308,37
60,2B USDP/E
36,4x
+14,1 vs self
Div yield
0,8 %
-2,3 vs self
ROE
45,7 %
+38,2 vs self
CA
CAH—
Cardinal Health Inc
$235,60
57,0B USDP/E
36,7x
+14,4 vs self
Div yield
0,9 %
-2,2 vs self
ROE
-55,9 %
-63,4 vs self
DB
DB—
DB.V
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
RE
REGN—
REGENERON PHARMACEUTICALS, INC.
$757,99
81,0B USDP/E
15,5x
-6,9 vs self
Div yield
—
— vs self
ROE
14,2 %
+6,7 vs self
BI
BIIB—
BIOGEN INC.
$201,74
29,6B USDP/E
21,3x
-1,0 vs self
Div yield
—
— vs self
ROE
7,5 %
0,0 vs self
ZT
ZTS—
Zoetis Inc
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
GR
GRFS—
Grifols SA
$7,86
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,51
Predicted surprise
+0,00
Beat probability
45 %
Analysts
3
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-25 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$11,00
Mean$12,33
Median$13,00
High$13,00
Spot$0,20
+5916.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-14,4 %Below median
Net Margin-19,4 %Below median
ROE-4,2 %Below median
Capex / Rev-0,2 %Above median
D/E0,22Below median
Cash Conv-0,70Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net flat24 grants17 insiders
- VP, Marketing & Sales · Employee Stock Option (right to buy) → Ordinary SharesAcquired 15 000 @ $5,87grant · 2026-04-07
- VP, General Counsel · Employee Stock Option (right to buy) → Ordinary SharesAcquired 10 000 @ $5,33grant · 2026-04-07
- VP, General Counsel · Employee Stock Option (right to buy) → Ordinary SharesDisposed 9 485 @ $5,58disposition · 2026-04-07
- VP, General Counsel · Employee Stock Option (right to buy) → Ordinary SharesAcquired 9 485 @ $5,33grant · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 4 000 @ $6,23disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 4 000 @ $5,98grant · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 7 500 @ $6,12disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 7 500 @ $5,87grant · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 6 625 @ $7,48disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 6 625 @ $7,23grant · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 4 000 @ $6,23disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 4 000 @ $5,98grant · 2026-04-07
- VP, Marketing & Sales · Employee Stock Option (right to buy) → Ordinary SharesDisposed 15 000 @ $6,12disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 7 500 @ $6,12disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 7 500 @ $5,87grant · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesDisposed 6 625 @ $7,48disposition · 2026-04-07
- Director · Employee Stock Option (right to buy) → Ordinary SharesAcquired 6 625 @ $7,23grant · 2026-04-07
- Chief Executive Officer · Employee Stock Option (right to buy) → Ordinary SharesDisposed 100 000 @ $6,12disposition · 2026-04-07
- Chief Executive Officer · Employee Stock Option (right to buy) → Ordinary SharesAcquired 100 000 @ $5,87grant · 2026-04-07
- VP Human Resources · Employee Stock Option (right to buy) → Ordinary SharesDisposed 15 000 @ $7,50disposition · 2026-04-07
- VP Human Resources · Employee Stock Option (right to buy) → Ordinary SharesAcquired 15 000 @ $7,25grant · 2026-04-07
- VP Human Resources · Employee Stock Option (right to buy) → Ordinary SharesDisposed 10 000 @ $5,29disposition · 2026-04-07
- VP Human Resources · Employee Stock Option (right to buy) → Ordinary SharesAcquired 10 000 @ $5,04grant · 2026-04-07
- VP, BD and Strategic Programs · Employee Stock Option (right to buy) → Ordinary SharesAcquired 3 750 @ $9,13grant · 2026-04-07
- VP, BD and Strategic Programs · Employee Stock Option (right to buy) → Ordinary SharesDisposed 3 750 @ $9,38disposition · 2026-04-07
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- KMDA.KL Market data — financials · 2026-05-28
- Kamdar Group (M) Bhd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,10 %$494M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
— missing data
Short positioning
130.7Kshares short-14.8% vs prior
4.87days to cover
57.6%short of daily vol
1.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
KMDA.KLCanonical
Bursa Malaysia · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSuppliers
Evidence & claims
From filings & derived data- Current liabilities (annual): USD 222KSEC XBRL filing
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-04-07 00:00 UTCINSIDER48 insider transactions — 2026-04 48 derivative
2026-04-07INSIDERRECANATI LEON acquired 6.6k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERReshef Liron acquired 15.0k sh Employee Stock Option (right to buy) — VP Human Resources
2026-04-07INSIDERReshef Liron disposed of 15.0k sh Employee Stock Option (right to buy) — VP Human Resources
2026-04-07INSIDERLondon Amir acquired 100.0k sh Employee Stock Option (right to buy) — Chief Executive Officer
2026-04-07INSIDERLondon Amir disposed of 100.0k sh Employee Stock Option (right to buy) — Chief Executive Officer
2026-04-07INSIDERGoldwasser Karnit acquired 6.6k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERGoldwasser Karnit disposed of 6.6k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERGoldwasser Karnit acquired 7.5k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERGoldwasser Karnit disposed of 7.5k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERNeheman Hanni acquired 15.0k sh Employee Stock Option (right to buy) — VP, Marketing & Sales
2026-04-07INSIDERNeheman Hanni disposed of 15.0k sh Employee Stock Option (right to buy) — VP, Marketing & Sales
2026-04-07INSIDERITSHAYEK ASSAF acquired 4.0k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERITSHAYEK ASSAF disposed of 4.0k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERRECANATI LEON disposed of 6.6k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERRECANATI LEON acquired 7.5k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERRECANATI LEON disposed of 7.5k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERDekel Benjamin acquired 4.0k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERDekel Benjamin disposed of 4.0k sh Employee Stock Option (right to buy) — Director
2026-04-07INSIDERLivneh Nir acquired 9.5k sh Employee Stock Option (right to buy) — VP, General Counsel
2026-04-07INSIDERLivneh Nir disposed of 9.5k sh Employee Stock Option (right to buy) — VP, General Counsel
2026-04-07INSIDERLivneh Nir acquired 10.0k sh Employee Stock Option (right to buy) — VP, General Counsel
2026-04-07INSIDERLivneh Nir disposed of 15.0k sh Employee Stock Option (right to buy) — VP, General Counsel
2026-04-07INSIDERBeladev Shavit disposed of 15.0k sh Employee Stock Option (right to buy) — VP Plasma Operations
2026-04-07INSIDERNir Eran acquired 22.5k sh Employee Stock Option (right to buy) — VP, Operations
2026-04-07INSIDERNir Eran disposed of 22.5k sh Employee Stock Option (right to buy) — VP, Operations
Showing the 40 most recent of 41 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage